A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Eligibility Criteria

• * Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF)
• * Able and willing to comply with protocol visits and procedures
• * Aged ≥ 18 years
• * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
• * Tumor types as below:
• * Adequate organ and bone marrow function.
• * Have at least 1 extracranial measurable tumor lesion.
• * Adequate archival formalin-fixed paraffin embedded （FFPE） tissue from prior biopsy.
• * Prior treatment with an agent targeting CDH17
• * Prior discontinuation of a topoisomerase I inhibitor due to treatment-related toxicities.
• * Have received a topoisomerase I inhibitor within protocol defined time before the first dose of study drug.
• * Have received an ADC consisting of a topoisomerase I inhibitor.
• * Concurrent enrollment in another clinical study, unless it is an observational clinical study.
• * Inadequate washout period for prior anticancer treatment before the first dose of study drug
• * Undergone major surgery within 4 weeks before the first dose of study drug or expect major surgery during the study.
• * Received long term systemic steroids or other immunosuppressive therapy within 2 weeks before the first dose of study drug.
• * Received any live vaccine within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study.
• * Diagnosis or evidence of spinal cord compression or leptomeningeal carcinomatosis.
• * Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases.
• * A history of non-infectious interstitial lung disease (ILD)/pneumonitis that requires steroids, current active ILD/pneumonitis.
• * Have clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.
• * Uncontrolled third-space fluid that requires repeated drainage.
• * Digestive system disease that may cause bleeding, perforation, jaundice, gastrointestinal obstruction.
• * An active tuberculosis based on medical history.
• * Known human immunodeficiency virus (HIV) infection.
• * Active hepatitis C infection.